{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.24","upperLimit":"2.25","value":"1.67"}]}],"title":"Hazard ratio: ECOG performance status of 1 (vs. 0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.36","upperLimit":"8.44","value":"3.39"}]}],"title":"Hazard ratio: ECOG performance status of 2 (vs. 0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.04","upperLimit":"1.07","value":"1.05"}]}],"title":"Hazard ratio: Age"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.27","upperLimit":"2.28","value":"1.71"}]}],"title":"Hazard ratio: Sex of male (vs. female)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.44","upperLimit":"1.52","value":"0.81"}]}],"title":"Hazard ratio: Primary site of transverse colon (vs. Right-side colon)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.82","upperLimit":"1.55","value":"1.13"}]}],"title":"Hazard ratio: Primary site of left-side colon (vs. Right-side colon)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.39","upperLimit":"5.17","value":"2.68"}]}],"title":"Hazard ratio: Primary site of other (vs. Right-side colon)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.96","upperLimit":"0.99","value":"0.98"}]}],"title":"Hazard ratio: Number of lymph nodes"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1368"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the time from randomization to death from any cause. OS is censored at the date of last contact for patients still alive. The following patient/tumor characteristics were associated with overall survival:\n\n* ECOG Performance Status (0, 1, or 2)\n* Age\n* Sex (male, female)\n* Primary tumor site (right-side colon, transverse colon, left-side colon, or other)\n* Number of regional lymph nodes\n\nHazard ratios with adjustment for other covariates are reported with OS as the outcome variable.","dispersionType":"95% Confidence Interval","groups":[{"description":"Eligible patients who had advanced to step 2 (Arms A, B and C) and had complete data on patient/tumor characteristics are included.","id":"OG000","title":"Tumor Biological Characteristics and Overall Survival Analysis"}],"paramType":"NUMBER","populationDescription":"Eligible patients who had advanced to step 2 (Arms A, B and C) and had complete data on patient/tumor characteristics are included.","reportingStatus":"POSTED","timeFrame":"Assessed at baseline, every 3 months for patients within 2 years of step 2 randomization, every 6 months during 3-5 years from step 2 randomization, and then every 12 months until 10 years from step 2 randomization","title":"The Impact of Tumor Biological Characteristics on Overall Survival","type":"SECONDARY","unitOfMeasure":"hazard ratio"}